Status:
RECRUITING
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
Lead Sponsor:
Nantes University Hospital
Conditions:
Hemophilia A
Eligibility:
All Genders
18+ years
Brief Summary
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the ...
Eligibility Criteria
Inclusion
- Patient population with acquired hemophilia A:
- Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
- Obtaining signed and written informed consent for biocollection consent.
- Population of Patients with constitutional hemophilia A:
- Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.
- Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
- Obtaining signed and written informed consent for biocollection consent.
- Population of control subjects:
- Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.
- Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
- Obtaining signed and written informed consent for biocollection consent.
- Patient population with inflammatory pathology:
- Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.
- Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
- Obtaining signed and written informed consent for biocollection consent.
Exclusion
- For the 4 groups:
- Minor patient, under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion less than 7 days old.
- Treatment with corticosteroids in the 7 days preceding inclusion or any other immunomodulatory or immunosuppressive treatment in the 4 weeks preceding inclusion.
Key Trial Info
Start Date :
November 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04805021
Start Date
November 30 2021
End Date
June 30 2025
Last Update
March 21 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France
2
CH de Saint Nazaire
Saint-Nazaire, France